- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Prestige BioPharma Plans Investment to Boost Its Drug Pipeline
Prestige BioPharma aims to expand its drug pipeline with a $152 million research and development facility.
Prestige BioPharma, a Singapore-based company that has a trastuzumab biosimilar (HD201) under regulatory review, said it will build a $152 million research and development facility measuring 45,000 square meters in Busan, Republic of Korea.
The company recently signed a memorandum of understanding with the Busan City government, which in this project is celebrating the construction of its first biopharmaceutical center. Prestige said it would staff the facility over the next 5 years with 209 workers with PhDs and research and development skills.
HD201 recently completed a phase 3 clinical trial and is under review for approval by the European Medicines Agency (EMA). The Prestige pipeline also includes bevacizumab (HD204) and adalimumab (PBP1502) biosimilar candidates. HD204 is in phase 3 development, and the adalimumab candidate is in phase 1.
In addition, Prestige has a first-in-class antibody (PBP1510) under development for pancreatic cancer that targets pancreatic adenocarcinoma upregulated factor. The drug has received orphan designations from the FDA, the EMA, and the Korean Ministry of Food and Drug Safety. These designations streamline the development and review processes that precede marketing approval.
Prestige has also begun a venture into vaccine development and production and participated in the production of Russia’s Sputnik 5 COVID-19 vaccine.
“Prestige BioPharma will be able to accelerate the development of innovative antibody drugs and at the same time contribute to the growing global demands of vaccines in response to COVID-19 and potential future pandemics,” said Lisa S. Park, CEO, in a statement.
In April 2021, Prestige announced an agreement with Pharmapark, of Moscow, Russia, for the distribution of Prestige’s HD204 in Russia. The monoclonal antibody inhibits the growth of tumors and is useful in the treatment of multiple forms of cancer, including colorectal cancer, non–small cell lung cancer, and kidney cancer, among others.
For more about Prestige BioPharma's growth strategy, click here.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Infliximab Biosimilar Switch Due to Flare Risk: Monitoring Patients Is Crucial for Pharmacists
June 5th 2025Switching from reference infliximab to biosimilars (infliximab-abda and infliximab-dyyb) for rheumatic diseases may lead to treatment delays and a higher risk of disease flares, particularly when the switch is mandated by insurance.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
British Columbia’s Biosimilar Policy Shows No Impact on Hospital Visits
May 28th 2025Despite a dramatic shift toward biosimilar use following British Columbia’s policy, researchers found no rise in hospital visits or complications, underscoring the real-world reliability of etanercept biosimilars in managing inflammatory arthritis.
